JPS6115842A - インターフエロンと腫瘍壊死因子の相剰作用混合物 - Google Patents
インターフエロンと腫瘍壊死因子の相剰作用混合物Info
- Publication number
- JPS6115842A JPS6115842A JP60135823A JP13582385A JPS6115842A JP S6115842 A JPS6115842 A JP S6115842A JP 60135823 A JP60135823 A JP 60135823A JP 13582385 A JP13582385 A JP 13582385A JP S6115842 A JPS6115842 A JP S6115842A
- Authority
- JP
- Japan
- Prior art keywords
- interferon
- necrosis factor
- tumor necrosis
- ifn
- mixture
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 102000014150 Interferons Human genes 0.000 title claims abstract description 36
- 108010050904 Interferons Proteins 0.000 title claims abstract description 36
- 239000000203 mixture Substances 0.000 title claims abstract description 32
- 229940079322 interferon Drugs 0.000 title claims abstract description 30
- 108060008682 Tumor Necrosis Factor Proteins 0.000 title claims abstract description 12
- 102000003390 tumor necrosis factor Human genes 0.000 title claims abstract description 12
- 230000002195 synergetic effect Effects 0.000 title abstract description 3
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 4
- 101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 claims description 17
- 108010074328 Interferon-gamma Proteins 0.000 claims description 16
- 102000006992 Interferon-alpha Human genes 0.000 claims description 13
- 108010047761 Interferon-alpha Proteins 0.000 claims description 13
- 102000008070 Interferon-gamma Human genes 0.000 claims description 10
- 201000010099 disease Diseases 0.000 claims description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 4
- 102000057041 human TNF Human genes 0.000 claims description 3
- 229960003130 interferon gamma Drugs 0.000 claims description 3
- 230000001613 neoplastic effect Effects 0.000 claims description 3
- 102000002227 Interferon Type I Human genes 0.000 claims 2
- 108010014726 Interferon Type I Proteins 0.000 claims 2
- 206010028851 Necrosis Diseases 0.000 claims 1
- 239000000969 carrier Substances 0.000 claims 1
- 238000010353 genetic engineering Methods 0.000 claims 1
- 230000017074 necrotic cell death Effects 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 28
- 241001465754 Metazoa Species 0.000 abstract description 7
- 230000001028 anti-proliverative effect Effects 0.000 abstract description 3
- 210000005170 neoplastic cell Anatomy 0.000 abstract 1
- 230000009826 neoplastic cell growth Effects 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 32
- 102100040247 Tumor necrosis factor Human genes 0.000 description 14
- 108090000623 proteins and genes Proteins 0.000 description 14
- 102000004169 proteins and genes Human genes 0.000 description 13
- OHDXDNUPVVYWOV-UHFFFAOYSA-N n-methyl-1-(2-naphthalen-1-ylsulfanylphenyl)methanamine Chemical compound CNCC1=CC=CC=C1SC1=CC=CC2=CC=CC=C12 OHDXDNUPVVYWOV-UHFFFAOYSA-N 0.000 description 10
- 102100037850 Interferon gamma Human genes 0.000 description 6
- 231100000433 cytotoxic Toxicity 0.000 description 6
- 230000001472 cytotoxic effect Effects 0.000 description 6
- 229940044627 gamma-interferon Drugs 0.000 description 6
- 229940047124 interferons Drugs 0.000 description 6
- 241000282412 Homo Species 0.000 description 5
- 125000003275 alpha amino acid group Chemical group 0.000 description 5
- 239000000824 cytostatic agent Substances 0.000 description 5
- 230000001085 cytostatic effect Effects 0.000 description 5
- 241000588724 Escherichia coli Species 0.000 description 4
- 102100026720 Interferon beta Human genes 0.000 description 4
- 108090000467 Interferon-beta Proteins 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 206010008342 Cervix carcinoma Diseases 0.000 description 3
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 3
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 3
- 201000010881 cervical cancer Diseases 0.000 description 3
- 201000005202 lung cancer Diseases 0.000 description 3
- 208000020816 lung neoplasm Diseases 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 2
- 235000017166 Bambusa arundinacea Nutrition 0.000 description 2
- 235000017491 Bambusa tulda Nutrition 0.000 description 2
- 241001330002 Bambuseae Species 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 241000710188 Encephalomyocarditis virus Species 0.000 description 2
- 235000015334 Phyllostachys viridis Nutrition 0.000 description 2
- 239000011425 bamboo Substances 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 230000009036 growth inhibition Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 201000001441 melanoma Diseases 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- UGFAIRIUMAVXCW-UHFFFAOYSA-N Carbon monoxide Chemical compound [O+]#[C-] UGFAIRIUMAVXCW-UHFFFAOYSA-N 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- 239000006145 Eagle's minimal essential medium Substances 0.000 description 1
- 244000292411 Excoecaria agallocha Species 0.000 description 1
- 241000545744 Hirudinea Species 0.000 description 1
- 101001054334 Homo sapiens Interferon beta Proteins 0.000 description 1
- 101000599940 Homo sapiens Interferon gamma Proteins 0.000 description 1
- 108010074338 Lymphokines Proteins 0.000 description 1
- 102000008072 Lymphokines Human genes 0.000 description 1
- 101001054328 Mus musculus Interferon beta Proteins 0.000 description 1
- 101001044384 Mus musculus Interferon gamma Proteins 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 238000005571 anion exchange chromatography Methods 0.000 description 1
- 208000010123 anthracosis Diseases 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 230000008512 biological response Effects 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 238000001311 chemical methods and process Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000005289 controlled pore glass Substances 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 230000002008 hemorrhagic effect Effects 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 210000005265 lung cell Anatomy 0.000 description 1
- -1 lymphoxin Proteins 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 102000006240 membrane receptors Human genes 0.000 description 1
- 108020004084 membrane receptors Proteins 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 230000001617 migratory effect Effects 0.000 description 1
- 108700029353 mouse Ifna Proteins 0.000 description 1
- LWGJTAZLEJHCPA-UHFFFAOYSA-N n-(2-chloroethyl)-n-nitrosomorpholine-4-carboxamide Chemical compound ClCCN(N=O)C(=O)N1CCOCC1 LWGJTAZLEJHCPA-UHFFFAOYSA-N 0.000 description 1
- 230000017066 negative regulation of growth Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19843423234 DE3423234A1 (de) | 1984-06-23 | 1984-06-23 | Synergistische mischungen von interferonen und tumor-nekrose-faktor |
| DE3423234.6 | 1984-06-23 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JPS6115842A true JPS6115842A (ja) | 1986-01-23 |
Family
ID=6238998
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP60135823A Pending JPS6115842A (ja) | 1984-06-23 | 1985-06-21 | インターフエロンと腫瘍壊死因子の相剰作用混合物 |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US4791101A (OSRAM) |
| EP (1) | EP0170843B1 (OSRAM) |
| JP (1) | JPS6115842A (OSRAM) |
| AT (1) | ATE82508T1 (OSRAM) |
| AU (2) | AU593212B2 (OSRAM) |
| CA (1) | CA1258426A (OSRAM) |
| DD (2) | DD250053A5 (OSRAM) |
| DE (2) | DE3423234A1 (OSRAM) |
| DK (1) | DK282585A (OSRAM) |
| GR (1) | GR851492B (OSRAM) |
| HU (1) | HU206270B (OSRAM) |
| IE (1) | IE59289B1 (OSRAM) |
| IL (1) | IL75597A (OSRAM) |
| NZ (1) | NZ212513A (OSRAM) |
| PH (1) | PH24406A (OSRAM) |
| ZA (1) | ZA854682B (OSRAM) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS62215535A (ja) * | 1986-01-24 | 1987-09-22 | ジエネンテク，インコ−ポレイテツド | ウイルス感染の予防および治療用組成物 |
| JPS62242629A (ja) * | 1986-04-09 | 1987-10-23 | シタス コ−ポレイシヨン | 腫瘍壊死因子を含んで成る組成物 |
| US11713216B2 (en) * | 2020-11-02 | 2023-08-01 | Otis Elevator Company | Safety exit assembly for elevator car, and elevator system |
Families Citing this family (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4879226A (en) * | 1984-04-06 | 1989-11-07 | Asahi Kasei Kogyo Kabushiki Kaisha | Novel human physiologically active polypeptide |
| DE3423234A1 (de) * | 1984-06-23 | 1986-02-06 | Boehringer Ingelheim International GmbH, 6507 Ingelheim | Synergistische mischungen von interferonen und tumor-nekrose-faktor |
| EP0216786B1 (en) * | 1984-12-21 | 1992-03-18 | Biogen, Inc. | Purification, production and use of tumor necrosis factors |
| US4828830A (en) * | 1986-01-24 | 1989-05-09 | Genentech, Inc. | Method and composition for prophylaxis and treatment of viral infections |
| US4822605A (en) * | 1986-02-18 | 1989-04-18 | Exovir, Inc. | Compositions and methods employing the same for the treatment of viral and cancerous skin lesions and the like |
| CA1291706C (en) * | 1986-04-03 | 1991-11-05 | Alfred Rudolph | COMBINATION THERAPY USING INTERFERON-.beta. AND INTERLEUKIN-2 |
| US4863727A (en) * | 1986-04-09 | 1989-09-05 | Cetus Corporation | Combination therapy using interleukin-2 and tumor necrosis factor |
| US5425940A (en) * | 1986-04-09 | 1995-06-20 | Cetus Oncology Corporation | Combination therapy using interleukin-2 and tumor necrosis factor |
| PT85076B (pt) * | 1986-06-16 | 1990-07-31 | Genentech Inc | Metodo para o tratamento de doencas infecciosas pela administracao de factor de necrose tumoral-alfa |
| US5362490A (en) * | 1986-07-25 | 1994-11-08 | Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo | Human myelomonocyte interferon-gamma, and process for preparation and use thereof |
| IL80005A (en) * | 1986-09-10 | 1992-11-15 | Yeda Res & Dev | Compositions for modulating the effect of tnf and il-1 |
| US4929442A (en) * | 1986-09-26 | 1990-05-29 | Exovir, Inc. | Compositions suitable for human topical application including a growth factor and/or related materials |
| US4980160A (en) * | 1986-10-16 | 1990-12-25 | Biogen, Inc. | Combinations of tumor necrosis factors and anti-inflammatory agents and methods for treating malignant and non-malignant diseases |
| US4963354A (en) * | 1987-01-21 | 1990-10-16 | Genentech, Inc. | Use of tumor necrosis factor (TNF) as an adjuvant |
| DK0392300T3 (da) * | 1989-04-11 | 1992-09-28 | Boehringer Ingelheim Int | Anvendelse af lægemidler, der indeholder mindst et cytokin, til systemisk behandling af præneoplastiske læsioner |
| US6042837A (en) * | 1989-09-20 | 2000-03-28 | Kalland; Terje | Methods of staphylococcal enterotoxin directed cell-mediated cytotoxicity (SDCC) |
| US6126945A (en) * | 1989-10-03 | 2000-10-03 | Pharmacia Ab | Tumor killing effects of enterotoxins, superantigens, and related compounds |
| JPH07503851A (ja) * | 1992-02-10 | 1995-04-27 | インターフェロン・サイエンシズ、インコーポレイテッド | 改良インターフェロン及びヒトの末梢血液白血球からのその製造方法 |
| US5676942A (en) * | 1992-02-10 | 1997-10-14 | Interferon Sciences, Inc. | Composition containing human alpha interferon species proteins and method for use thereof |
| JP4066460B2 (ja) * | 1995-07-25 | 2008-03-26 | 東レ株式会社 | 骨疾患治療薬 |
| US6617171B2 (en) * | 1998-02-27 | 2003-09-09 | The General Hospital Corporation | Methods for diagnosing and treating autoimmune disease |
| US6599710B1 (en) | 1999-03-10 | 2003-07-29 | The General Hospital Corporation | Treatment of autoimmune disease |
| US20020091095A1 (en) * | 1999-12-13 | 2002-07-11 | Phillips Nigel C. | Modulation of Fas and FasL expression |
| CZ20022372A3 (cs) * | 1999-12-13 | 2002-11-13 | Bioniche Life Sciences Inc. | Terapeuticky pouľitelné syntetické oligonukleotidy |
| US7309694B2 (en) * | 2000-02-15 | 2007-12-18 | Fondazione Centro San Raffaele Del Monte Tabor | Modified cytokines for use in cancer therapy |
| IT1317835B1 (it) * | 2000-02-15 | 2003-07-15 | San Raffaele Centro Fond | Citochine modificate per uso nella terapia del cancro. |
| US7109303B2 (en) * | 2000-02-15 | 2006-09-19 | Fondazione Centro San Raffaele Del Monte Tabor | Modified cytokines for use in cancer therapy |
| US20030129162A1 (en) * | 2000-09-12 | 2003-07-10 | Lau Allan S. | Compositions comprising mixtures of therapeutic proteins and methods of producing the same |
| US20020150541A1 (en) * | 2000-09-12 | 2002-10-17 | Gene Trol Biotherapeutics, Inc. | Compositions comprising mixtures of therapeutic proteins and methods of producing the same |
| US20020150552A1 (en) * | 2000-09-12 | 2002-10-17 | Lau Allan S. | Compositions comprising mixtures of therapeutic proteins and methods of producing the same |
| DK1471974T3 (da) * | 2002-02-06 | 2007-12-03 | Ares Trading Sa | Tumornekrose-faktor kombineret med interferon ved demyeliniserende sygdomme |
| GB0209893D0 (en) * | 2002-04-30 | 2002-06-05 | Molmed Spa | Conjugate |
| GB0209896D0 (en) * | 2002-04-30 | 2002-06-05 | Molmed Spa | Conjugate |
| US7582313B2 (en) * | 2002-06-27 | 2009-09-01 | The General Hospital Corporation | Methods of organ regeneration using Hox 11-expressing pluripotent cells |
| US7628988B2 (en) | 2002-06-27 | 2009-12-08 | The General Hospital Corporation | Methods and compositions for treating type 1 diabetes |
| AU2003290948A1 (en) * | 2002-11-15 | 2004-06-15 | The General Hospital Corporation | Screening methods to identify treatments for autoimmune disease |
| EP1578799B8 (en) | 2002-12-02 | 2011-03-23 | Amgen Fremont Inc. | Antibodies directed to tumor necrosis factor and uses thereof |
| JP2007513083A (ja) * | 2003-11-10 | 2007-05-24 | アンジオテック インターナショナル アーゲー | 医療用移植片および繊維誘発剤 |
| US20080102054A1 (en) * | 2005-01-18 | 2008-05-01 | Faustman Denise L | Compositions Containing Agm Cells And Methods Of Use Thereof |
| DE102012024749A1 (de) | 2012-12-11 | 2014-06-26 | Martin Röcken | Tumorprävention und -therapie durch Induktion einer Tumorseneszenz |
| US9821010B2 (en) | 2013-02-07 | 2017-11-21 | The General Hospital Corporation | Methods for expansion or depletion of T-regulatory cells |
| JP6560200B2 (ja) | 2013-10-17 | 2019-08-14 | ザ ジェネラル ホスピタル コーポレイション | 自己免疫疾患の治療に応答性の対象を同定する方法およびそれを治療するための組成物 |
| EP3294773A1 (en) | 2015-05-15 | 2018-03-21 | The General Hospital Corporation | Antagonistic anti-tumor necrosis factor receptor superfamily antibodies |
| EP3340999A4 (en) | 2015-08-28 | 2019-06-12 | The General Hospital Corporation | AGONISTIC ANTI-TUMOR NECROSIS RECEPTOR 2 ANTIBODIES |
| US11266730B2 (en) | 2015-09-29 | 2022-03-08 | The General Hospital Corporation | Methods of treating and diagnosing disease using biomarkers for BCG therapy |
| US11859002B2 (en) | 2016-05-13 | 2024-01-02 | The General Hospital Corporation | Antagonistic anti-tumor necrosis factor receptor 2 antibodies |
| WO2019147837A2 (en) | 2018-01-24 | 2019-08-01 | Beijing Percans Oncology Co. Ltd. | Cytokine fusion proteins |
| CN113302205B (zh) | 2018-11-15 | 2024-12-06 | 综合医院公司 | 激动性肿瘤坏死因子受体超家族多肽 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5888322A (ja) * | 1981-11-21 | 1983-05-26 | Hayashibara Biochem Lab Inc | 標的細胞障害性因子を含有する悪性腫瘍治療剤とその製造方法 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE8204382L (sv) * | 1981-07-21 | 1983-01-22 | Hayashibara Biochem Lab | Sett att framstella malcellysfaktor och anvendning derav |
| ZA844070B (en) * | 1983-06-01 | 1984-12-24 | Genentech Inc | Gamma interferon-lymphotoxin synergism |
| CA1265444A (en) * | 1983-06-27 | 1990-02-06 | Lloyd J. Old | Effect of human tumor necrosis factor and human interferon on human cancer cells and methods |
| DE3421731A1 (de) * | 1984-06-12 | 1985-12-12 | Boehringer Ingelheim International GmbH, 6507 Ingelheim | Humaner-tumor-nekrose-faktor |
| DE3423234A1 (de) * | 1984-06-23 | 1986-02-06 | Boehringer Ingelheim International GmbH, 6507 Ingelheim | Synergistische mischungen von interferonen und tumor-nekrose-faktor |
-
1984
- 1984-06-23 DE DE19843423234 patent/DE3423234A1/de not_active Ceased
-
1985
- 1985-06-19 GR GR851492A patent/GR851492B/el unknown
- 1985-06-20 AT AT85107618T patent/ATE82508T1/de not_active IP Right Cessation
- 1985-06-20 EP EP85107618A patent/EP0170843B1/de not_active Expired - Lifetime
- 1985-06-20 PH PH32429A patent/PH24406A/en unknown
- 1985-06-20 DE DE8585107618T patent/DE3586833D1/de not_active Expired - Fee Related
- 1985-06-20 US US06/746,793 patent/US4791101A/en not_active Expired - Fee Related
- 1985-06-21 NZ NZ212513A patent/NZ212513A/xx unknown
- 1985-06-21 HU HU852456A patent/HU206270B/hu unknown
- 1985-06-21 IL IL75597A patent/IL75597A/xx not_active IP Right Cessation
- 1985-06-21 DD DD85295292A patent/DD250053A5/de not_active IP Right Cessation
- 1985-06-21 AU AU43931/85A patent/AU593212B2/en not_active Ceased
- 1985-06-21 ZA ZA854682A patent/ZA854682B/xx unknown
- 1985-06-21 CA CA000484739A patent/CA1258426A/en not_active Expired
- 1985-06-21 IE IE154785A patent/IE59289B1/en not_active IP Right Cessation
- 1985-06-21 JP JP60135823A patent/JPS6115842A/ja active Pending
- 1985-06-21 DK DK282585A patent/DK282585A/da not_active Application Discontinuation
- 1985-06-21 DD DD85277633A patent/DD238725A5/de not_active IP Right Cessation
- 1985-06-24 AU AU44167/85A patent/AU4416785A/en not_active Withdrawn
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5888322A (ja) * | 1981-11-21 | 1983-05-26 | Hayashibara Biochem Lab Inc | 標的細胞障害性因子を含有する悪性腫瘍治療剤とその製造方法 |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS62215535A (ja) * | 1986-01-24 | 1987-09-22 | ジエネンテク，インコ−ポレイテツド | ウイルス感染の予防および治療用組成物 |
| JPS62242629A (ja) * | 1986-04-09 | 1987-10-23 | シタス コ−ポレイシヨン | 腫瘍壊死因子を含んで成る組成物 |
| US11713216B2 (en) * | 2020-11-02 | 2023-08-01 | Otis Elevator Company | Safety exit assembly for elevator car, and elevator system |
Also Published As
| Publication number | Publication date |
|---|---|
| AU4416785A (en) | 1986-01-02 |
| DK282585A (da) | 1985-12-24 |
| IE59289B1 (en) | 1994-02-09 |
| IL75597A0 (en) | 1985-10-31 |
| HU206270B (en) | 1992-10-28 |
| EP0170843B1 (de) | 1992-11-19 |
| AU4393185A (en) | 1986-01-02 |
| EP0170843A1 (de) | 1986-02-12 |
| ZA854682B (en) | 1987-02-25 |
| AU593212B2 (en) | 1990-02-08 |
| DE3423234A1 (de) | 1986-02-06 |
| CA1258426A (en) | 1989-08-15 |
| PH24406A (en) | 1990-06-13 |
| NZ212513A (en) | 1988-08-30 |
| HUT37891A (en) | 1986-03-28 |
| ATE82508T1 (de) | 1992-12-15 |
| GR851492B (OSRAM) | 1985-11-25 |
| US4791101A (en) | 1988-12-13 |
| IE851547L (en) | 1985-12-23 |
| DD238725A5 (de) | 1986-09-03 |
| DE3586833D1 (de) | 1992-12-24 |
| DD250053A5 (de) | 1987-09-30 |
| IL75597A (en) | 1991-11-21 |
| DK282585D0 (da) | 1985-06-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPS6115842A (ja) | インターフエロンと腫瘍壊死因子の相剰作用混合物 | |
| Le et al. | Biology of disease | |
| Kishimoto | The biology of interleukin-6 | |
| Schoenhaut et al. | Cloning and expression of murine IL-12 | |
| Fransen et al. | Recombinant tumor necrosis factor: its effect and its synergism with interferon-γ on a variety of normal and transformed human cell lines | |
| Pestka et al. | Interleukin-10 and related cytokines and receptors | |
| Sayers et al. | Regulation of human natural killer cell activity by interferon-gamma: lack of a role in interleukin 2-mediated augmentation. | |
| JP2001520238A5 (OSRAM) | ||
| IL94052A (en) | Pharmaceutical preparations containing cytokines for the treatment of pre-neoplastic lesions and the use of the above cytokines | |
| Berent et al. | Sendai virus induces high levels of tumor necrosis factor mRNA in human peripheral blood leukocytes | |
| Fiers et al. | Lymphokines and monokines in anti-cancer therapy | |
| Czarniecki | The role of tumor necrosis factor in viral disease | |
| Hakoshima et al. | Crystallization and preliminary X-ray investigation reveals that tumor necrosis factor is a compact trimer furnished with 3-fold symmetry | |
| CZ2002195A3 (cs) | Farmaceutický prostředek pro inhibici produkce IL-18 | |
| Adolf | Structure and effects of interferon-gamma | |
| Brack et al. | Hematopoietic growth factors: interactions and regulation of production | |
| JPS63264500A (ja) | 新規ポリペプチドおよびその製造法 | |
| Fiers et al. | Structure–Functton Relationship of Tumour Necrosis Factor and its Mechanism of Action | |
| Langer et al. | Purification, bacterial expression, and biological activities of the human interferons | |
| Hasegawa et al. | SFA-2, a novel bZIP transcription factor induced by human T-cell leukemia virus type I, is highly expressed in mature lymphocytes | |
| Oritani et al. | Interferon-ζ/limitin: novel type I interferon that displays a narrow range of biological activity | |
| Rathjen et al. | Differential effects of small tumour necrosis factor-alpha peptides on tumour cell cytotoxicity, neutrophil activation and endothelial cell procoagulant activity | |
| Gase et al. | Critical role of the C-terminus in the biological activities of human tumour necrosis factor-alpha | |
| Ruggiero et al. | The in vitro antiviral activity of tumor necrosis factor (TNF) in WISH cells is mediated by IFN-β induction | |
| JP2564245B2 (ja) | ロイコレギュリン細胞表面レセプターに特異的なモノクローナル抗体、その製造法、及びその使用 |